MIT Technology Review September 26, 2024
Rhiannon Williams

Plus: OpenAI wants to become a for-profit

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.

Two Nobel Prize winners want to cancel their own CRISPR patents in Europe

In the decade-long fight to control CRISPR, the super-tool for modifying DNA, it’s been common for lawyers to try to overturn patents held by competitors. But now, in a surprise twist, the team that earned the Nobel Prize in chemistry for developing CRISPR is asking to cancel two of their own seminal patents, MIT Technology Review has learned.

­­The request to withdraw the pair of European patents, by lawyers for Emmanuelle Charpentier and Jennifer Doudna, comes...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Pharma / Biotech, Technology
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article